Literature DB >> 1883598

Effects of muscarinic receptor agonists and antagonists on dopamine-mediated behavioural paradigms.

S K Bhattacharya1, A P Sen.   

Abstract

The effects of some muscarinic M1 and M2 receptor agonists and antagonists on two dopamine-mediated behavioural paradigms, namely post-swim grooming response and apormorphine-induced climbing behaviour, was investigated in mice. The M1 agonists and M2 receptor antagonists attenuated both paradigms, whereas the M1 receptor antagonists and M2 receptor agonists facilitated both behaviours. However, carbachol and physostigmine, exhibited a similar dose-dependent dual effect with the lower doses augmenting and the higher doses inhibiting both the behaviours, suggesting that the M2 agonist receptor specificity is lost on dose increment. The findings indicate that the central cholinergic muscarinic heteroreceptors, like the other muscarinic receptors, are functionally divisible into M1 and M2 receptor subtypes in their modulation of dopaminergic activity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1883598     DOI: 10.1007/bf01244975

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  10 in total

Review 1.  Muscarinic receptor subtypes in the central nervous system.

Authors:  W Hoss; J Ellis
Journal:  Int Rev Neurobiol       Date:  1985       Impact factor: 3.230

Review 2.  Muscarinic receptor subtypes. Physiology and clinical implications.

Authors:  R K Goyal
Journal:  N Engl J Med       Date:  1989-10-12       Impact factor: 91.245

3.  Muscarine-binding sites localized to cortical dopamine terminals.

Authors:  D R Liskowsky; L T Potter
Journal:  Neurosci Lett       Date:  1985-07-31       Impact factor: 3.046

4.  Neuropharmacological studies on selective monoamine oxidase A and B inhibitors.

Authors:  M Mukhopadhyay; S N Upadhyay; S K Bhattacharya
Journal:  Indian J Exp Biol       Date:  1987-11       Impact factor: 0.818

5.  Post-swim grooming in mice inhibited by dopamine receptor antagonists and by cannabinoids.

Authors:  G B Chesher; D M Jackson
Journal:  Pharmacol Biochem Behav       Date:  1980-09       Impact factor: 3.533

6.  Muscarine receptor-mediated modulation of [3H]dopamine and [14C]acetylcholine release from rat neostriatal slices: selective antagonism by gallamine but not pirenzepine.

Authors:  A N Schoffelmeer; B J Van Vliet; G Wardeh; A H Mulder
Journal:  Eur J Pharmacol       Date:  1986-09-09       Impact factor: 4.432

7.  Heterogeneity of presynaptic muscarinic receptors regulating neurotransmitter release in the rat brain.

Authors:  M Raiteri; R Leardi; M Marchi
Journal:  J Pharmacol Exp Ther       Date:  1984-01       Impact factor: 4.030

8.  An in vivo method for testing GABAergic compounds.

Authors:  Y K Fung; A Novin-Baheran; T K Bosh; D R Grassman
Journal:  Pharmacol Biochem Behav       Date:  1982-10       Impact factor: 3.533

9.  On the presence in the cerebral cortex of muscarinic receptor subtypes which differ in neuronal localization, function and pharmacological properties.

Authors:  M Marchi; M Raiteri
Journal:  J Pharmacol Exp Ther       Date:  1985-10       Impact factor: 4.030

10.  The mesolimbic system, denervation and the climbing response in the mouse.

Authors:  B Costall; D H Fortune; R J Naylor; V Nohria
Journal:  Eur J Pharmacol       Date:  1980-08-29       Impact factor: 4.432

  10 in total
  3 in total

1.  Effects of muscarinic receptor agonists and antagonists on rat brain serotonergic activity.

Authors:  S K Bhattacharya; A P Sen
Journal:  J Neural Transm Gen Sect       Date:  1992

2.  Verticalization of behavior elicited by dopaminergic mobilization is qualitatively different between C57BL/6J and DBA/2J mice.

Authors:  E Tirelli; J M Witkin
Journal:  Psychopharmacology (Berl)       Date:  1994-10       Impact factor: 4.530

3.  Oxotremorine treatment reduces repetitive behaviors in BTBR T+ tf/J mice.

Authors:  Dionisio A Amodeo; Julia Yi; John A Sweeney; Michael E Ragozzino
Journal:  Front Synaptic Neurosci       Date:  2014-08-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.